Road to the Clinic for Biologic Therapeutics


Johnson & Johnson Innovation, JLABS and Janssen BioTherapeutics invite you to an in-depth look into the process of filing biologic Clinical Trial Authorisation (CTA) applications and the procedures necessary for advancing your company's early-stage drug development program. Whether your goal is to develop a pipeline through commercial launch, or partner as early as possible, submitting CTAs is a critical early milestone for every biotech company. With big Pharma and VC firms competing for the most promising compounds, startups are expected to demonstrate a solid plan for achieving CTA acceptance.


Go back